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Abstract
Background In heart failure (HF), levels of NT-proBNP are influenced by the presence of concomitant atrial fibrillation 
(AF), making it difficult to distinguish between HF versus AF in patients with raised NT-proBNP. It is unknown whether 
levels of GDF-15 are also influenced by AF in patients with HF. In this study we compared the plasma levels of NT-proBNP 
versus GDF-15 in patients with HF in AF versus sinus rhythm (SR).
Methods In a post hoc analysis of the index cohort of BIOSTAT-CHF (n = 2516), we studied patients with HF categorized 
into three groups: (1) AF at baseline (n = 733), (2) SR at baseline with a history of AF (n = 183), and (3) SR at baseline and 
no history of AF (n = 1025). The findings were validated in the validation cohort of BIOSTAT-CHF (n = 1738).
Results Plasma NT-proBNP levels of patients who had AF at baseline were higher than those of patients in SR (both with 
and without a history of AF), even after multivariable adjustment (3417 [25th–75th percentile 1897–6486] versus 1788 
[682–3870], adjusted p < 0.001, versus 2231 pg/mL [902–5270], adjusted p < 0.001). In contrast, after adjusting for clinical 
confounders, the levels of GDF-15 were comparable between the three groups (3179 [2062–5253] versus 2545 [1686–4337], 
adjusted p = 0.36, versus 2294 [1471–3855] pg/mL, adjusted p = 0.08). Similar patterns of both NT-proBNP and GDF-15 
were found in the validation cohort.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s0039 2-019-01513 -y) contains 
supplementary material, which is available to authorized users.
 * Adriaan A. Voors 
 a.a.voors@umcg.nl
1 Department of Cardiology, University of Groningen, 
University Medical Centre Groningen, Hanzeplein 1, 
9713 GZ Groningen, The Netherlands
2 Department of Cardiology, National Heart Centre Singapore, 
Singapore Duke-NUS Graduate Medical School, Singapore, 
Singapore
3 Department of Cardiovascular Sciences, University 
of Leicester, Groby Road, Leicester LE3 9QP, UK
4 NIHR Leicester Biomedical Research Centre, Glenfield 
Hospital, Groby Road, Leicester LE3 9QP, UK
5 Division of Molecular and Clinical Medicine, School 
of Medicine University of Dundee, Ninewells Hospital 
and Medical School, Dundee DD1 9SY, UK
6 University of Bergen, Bergen, Norway
7 Stavanger University Hospital, Stavanger, Norway
8 National Heart & Lung Institute, Royal Brompton & 
Harefield Hospitals, Imperial College, Sydney St, Chelsea, 
London SW3 6NP, UK
9 Robertson Institute of Biostatistics and Clinical Trials 
Unit, University of Glasgow, University Avenue, 
Glasgow G12 8QQ, UK
10 Inserm CIC 1433, Université de Lorrain, CHU de Nancy, 
Nancy, France
11 Department of Cardiology (CVK), and Berlin Institute 
of Health Center for Regenerative Therapies (BCRT), 
German Centre for Cardiovascular Research (DZHK) partner 
site Berlin, Charité Universitätsmedizin, Berlin, Germany
12 Department of Medical and Surgical Specialties, 
Radiological Sciences and Public Health, Institute 
of Cardiology, University of Brescia, Brescia, Italy
 Clinical Research in Cardiology
1 3
Conclusion These data show that in patients with HF, NT-proBNP is significantly influenced by underlying AF at time 
of measurement and not by previous episodes of AF, whereas the levels of GDF-15 are not influenced by the presence of 
AF. Therefore, GDF-15 might have additive value combined with NT-proBNP in the assessment of patients with HF and 
concomitant AF.
Graphic abstract
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Abbreviations
AF  Atrial fibrillation
BIOSTAT-CHF  The BIOlogy Study to Tailored Treat-
ment in Chronic Heart Failure
ECG  Electrocardiogram
GDF-15  Growth differentiation factor-15
HF  Heart failure
LVEF  Left ventricular ejection fraction
NT-proBNP  N-terminal pro-B-type natriuretic 
peptide
SR  Sinus rhythm
Introduction
N-terminal pro-B-type natriuretic peptide (NT-proBNP) 
plays an important role in the diagnosis and prognosis of 
heart failure (HF) [1, 2]. For the diagnosis of HF, this marker 
is known for its high sensitivity, but lower specificity, which 
makes NT-proBNP especially helpful to rule out HF [3]. 
Several other conditions, such as renal failure, pulmonary 
embolism and atrial fibrillation (AF), are also known to fur-
ther elevate NT-proBNP levels in patients with concomitant 
HF. AF in this regards is particularly important because it is 
highly prevalent among patients with HF regardless of ejec-
tion fraction, and mimics the symptoms (breathlessness) and 
signs (left atrial enlargement) of HF. Therefore, it is often 
unclear how elevated NT-proBNP levels in patients with HF 
and AF should be interpreted, since there are several poten-
tial explanations for these elevated levels [4–6]. First, NT-
proBNP elevations may be directly related to the immediate 
hemodynamic alterations during the actual episode of AF 
[7]. Secondly, elevated levels of NT-proBNP may be related 
to the chronic structural or functional cardiac remodeling as 
a result of sustained episodes of AF, or in the third place, 
just reflect that patients with AF have more advanced HF. In 
most contemporary clinical HF trials, different NT-proBNP 
thresholds are being used for inclusion of patients with and 
without AF, often without further differentiation between 
patients who only have a history of AF, and those who have 
AF at time of enrollment.
In the past years, many markers have been shown to have 
strong prognostic value in HF, of which growth differentia-
tion factor-15 (GDF-15) is amongst the best established ones 
[8–11]. GDF-15 is a protein belonging to the transforming 
growth factor-beta superfamily, and has a role in inflam-
matory and apoptotic cell processes, and is produced by 
multiple organs, including the heart [12–14]. It is, however, 
unknown how the plasma levels of GDF-15 are influenced 
by underlying AF in patients with HF. The search for a bio-
marker that is less influenced by underlying AF than NT-
proBNP is, could be of help in the assessment of patients 
with both HF and AF.
To investigate whether the levels of GDF-15 are simi-
larly elevated as NT-proBNP by concomitant AF in patients 
with HF, we performed a post hoc analysis of these two 
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biomarkers in The BIOlogy Study to Tailored Treatment in 
Chronic Heart Failure (BIOSTAT-CHF) [15].
Methods
Patient population and definitions
In the multinational, prospective, observational index cohort 
of BIOSTAT-CHF, 2516 patients with new-onset or worsen-
ing signs and/or symptoms of HF from 11 European coun-
tries were included between 2010 and 2012 [15]. Patients 
had to have evidence of cardiac dysfunction documented 
either by left ventricular ejection fraction (LVEF) of ≤ 40% 
or plasma concentrations of NT-proBNP > 2000 pg/mL (this 
cutoff was the same for patients in sinus rhythm [SR] and 
AF). A comparable validation cohort of BIOSTAT-CHF 
included another 1738 patients from six centers in Scot-
land between 2010 and 2014, who had to have a previously 
documented admission for HF. No additional LVEF or NT-
proBNP was used for the validation cohort, which resulted 
in a higher percentage of patients with heart failure with 
preserved ejection fraction (HFpEF, 34% in the validation 
cohort versus 7% in the index cohort).
In both cohorts, a standard 12-lead electrocardiogram 
(ECG) was performed at baseline, generally on the same 
day as the time of blood draw for biomarker measurements 
(median difference of 0 days with 25th–75th percentile 
[Q1–Q3] from − 2 to + 2 days. Patients were categorized 
into three groups based on history and baseline ECG: (1) 
AF at baseline, (2) history of AF but in SR at baseline, and 
(3) SR at baseline and no previously documented episode 
of AF. Patients with a rhythm other than SR or AF on the 
baseline ECG were excluded (pacemaker rhythm, n = 283, 
and unknown rhythm, n = 55) [16]. The study was conducted 
according to the Declaration of Helsinki, approved by the 
medical ethics committees of participating centers, and all 
patients provided informed consent.
Biomarkers
Measurement of NT-proBNP and GDF-15 was performed 
at baseline. The levels of NT-proBNP and GDF-15 were 
measured using electrochemiluminescence on a cobas e 
411 analyzer, using standard methods (Roche Diagnostics 
GmbH, Mannheim, Germany) [17, 18].
Statistical analyses
Normally distributed variables were displayed as mean 
with standard deviation, non-normally distributed vari-
ables as median with 25th–75th percentile, and categorical 
variables as numbers with percentages. Group differences 
were assessed with t tests and one-way analysis of variance 
for normally distributed variables, Kruskal–Wallis and 
Mann–Whitney U tests for non-normally distributed con-
tinuous variables, and χ2 tests for categorical variables. Mul-
tiple linear regression models were used to investigate the 
associations between NT-proBNP and GDF-15 and the three 
rhythm groups. Natural transformed biomarkers were used 
in the regression analyses. Potential and known confound-
ers of the two biomarkers were included in the regression 
model, including age, sex, body mass index (BMI), LVEF, 
heart rate, renal disease [estimated glomerular filtration rate 
(eGFR) using the Chronic Kidney Disease Epidemiology 
Collaboration (CKD-EPI) formula], a previous myocardial 
infarction, diabetes mellitus, and the use of ACE-inhibitors/
ARBs and beta-blockers at baseline. To test which variables 
had the strongest association with elevated levels of NT-
proBNP and GDF-15, both biomarkers were analyzed as a 
dependent variable in uni- and multi-variable linear regres-
sion analysis. The multivariable models were built with all 
variables with p < 0.10 in the univariable analysis, after 
which backward elimination was performed. Variables that 
had the strongest associations in both the index and valida-
tion cohort were displayed in the final multivariable model. 
A p value of < 0.1 was considered significant for testing 
interactions. p values of < 0.05 were considered statistically 
significant in all other analyses. All analyses were conducted 
with R version 3.5.2 (R Foundation for Statistical Comput-
ing, Vienna, Austria).
Results
Index cohort
A total of 1941 patients with HF were studied, of whom 733 
patients had AF at baseline, 183 patients had a history of 
AF but were in SR at baseline, and 1025 had SR at baseline 
and no previously documented episode of AF. The charac-
teristics of the patients within these three rhythm groups are 
summarized in Table 1. Main findings were that patients 
with AF at baseline were significantly older, had a higher 
BMI and higher heart rate, and less often had a previous 
myocardial infarction as compared with the two other groups 
who were in SR at baseline.
The plasma levels of NT-proBNP were significantly 
higher in patients who had AF at baseline, with a median 
of 3417 pg/mL (1897–6486), as compared with patients 
who were in SR at baseline; both those who had a history 
of AF (1788 pg/mL [682–3870], p < 0.001) and those who 
never had AF before (1588 pg/mL [902–5270], p < 0.001) 
(Table 1), also after multivariable adjustment (Table 2). In 
univariable analysis, the levels of GDF-15 were also highest 
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in patients with AF at baseline and lowest in patients who 
were in SR at baseline (Table 1), but after adjusting for clini-
cal confounders, the levels of GDF-15 between patients with 
AF at baseline and those in SR with and without previous 
AF were comparable (Table 2).
Validation cohort
Baseline characteristics of the validation cohort were gen-
erally comparable to the index cohort of BIOSTAT-CHF 
(Supplementary Table 1). As discussed previously, a higher 
number of patients with HFpEF were included in the valida-
tion cohort, which resulted in a higher number of women, 
a higher LVEF, and lower levels of NT-proBNP in all three 
groups. Despite these differences in baseline characteristics, 
similar patterns of plasma levels of both NT-proBNP and 
GDF-15 were found in the validation cohort as compared to 
the index cohort. Patients with AF at baseline had a median 
NT-proBNP of 2105 pg/mL (1015–4472), which was signifi-
cantly higher than those who had a history of AF but were in 
SR at baseline (1063 [440–4094], p < 0.001) and patients in 
SR who never had AF before (874 [314–2758]). The levels 
of GDF-15 were comparable among the three groups after 
multivariable adjustment (Table 2). No significant inter-
actions between the biomarkers and the rhythm groups in 
heart failure with reduced ejection fraction (HFrEF) versus 
HFpEF were found in both the index and validation cohort.
Table 1  Baseline characteristics of the index cohort, stratified by heart rhythm
AF atrial fibrillation, SR sinus rhythm, BMI body mass index, NYHA New York Heart Association, LVEF left ventricular ejection fraction, 
COPD chronic obstructive pulmonary disease, ACE angiotensin converting enzyme, ARB angiotensin receptor blockers, eGFR estimated glo-
merular filtration rate, NT-proBNP N-terminal pro-B-type natriuretic peptide, GDF15 growth differentiation factor 15
Clinical characteristic AF at baseline
N = 733 (38%)
History of AF–SR at baseline
N = 183 (9%)
Sinus rhythm
N = 1025 (53%)
P for trend
Age (years) 76 ± 10 72 ± 11 70 ± 13 < 0.001
Women (%) 182 (25) 51 (28) 301 (29) 0.110
BMI (kg/m2) 28.5 ± 5.6 28.3 ± 5.1 27.5 ± 5.5 0.001
NYHA (%) 0.010
 I/II 202 (28) 68 (37) 331 (32)
 III 233 (36) 37 (23) 270 (31)
 IV 28 (4) 7 (4) 33 (4)
LVEF, % 33 ± 12 33 ± 11 29 ± 10 < 0.001
Systolic blood pressure (mmHg) 125 ± 22 126 ± 24 126 ± 22 0.780
Diastolic blood pressure (mmHg) 76 ± 14 75 ± 16 75 ± 13 0.188
Heart rate (beats/min) 93 ± 25 73 ± 16 79 ± 18 < 0.001
History of (%)
 Myocardial infarction 215 (29) 67 (37) 431 (42) < 0.001
 Stroke 83 (11) 27 (15) 72 (7) < 0.001
 Hypertension 470 (64) 118 (65) 623 (61) 0.300
 Diabetes mellitus 232 (32) 63 (34) 320 (31) 0.691
 COPD 133 (18) 46 (25) 150 (15) 0.001
Medication (%)
 ACE-inhibitors/ARBs 504 (69) 135 (74) 770 (75) 0.012
 Beta-blockers 599 (82) 160 (87) 850 (83) 0.185
 Loop diuretics 732 (100) 183 (100) 1024 (100) 0.873
 Amiodarone 92 (13) 67 (37) 117 (11) < 0.001
 Digoxin 282 (39) 21 (12) 72 (7) < 0.001
 Verapamil/diltiazem 18 (3) 4 (2) 7 (1) 0.008
 Class 1c antiarrhythmic drugs 2 (1) 5 (3) 2 (1) < 0.001
 Ivabradine 0 (0) 2 (1) 26 (3) < 0.001
Laboratory data
 eGFR 58.0 ± 21.8 59.2 ± 20.8 66.0 ± 23.4 < 0.001
 NT-proBNP (pg/mL) 3417 [1897, 6486] 1788 [682, 3870] 2231 [902, 5270] < 0.001
 GDF-15 (pg/mL) 3197 [2062, 5253] 2545 [1686, 4337] 2294 [1471, 3855] < 0.001
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Correlates of NT‑proBNP versus GDF‑15
The multivariable models with the correlates of elevated lev-
els of NT-proBNP and GDF-15 are presented in Table 3. AF 
at baseline was strongly associated with elevated levels of 
NT-proBNP in both the index and validation cohort. Other 
variables that were strongly associated with elevated lev-
els of NT-proBNP were age, BMI, LVEF and eGFR. AF at 
baseline was not associated with higher levels of GDF-15 in 
the multivariable model. Variables that were strongly associ-
ated with higher levels of GDF-15 in both cohorts were age, 
systolic blood pressure, diabetes mellitus and eGFR.
Discussion
These data suggest that in patients with HF, after adjust-
ment for clinical confounders, the levels of NT-proBNP, but 
not GDF-15, are significantly influenced by the presence of 
AF at time of measurement. GDF-15 is mainly produced in 
non-cardiac and peripheral tissues, such as endothelial cells 
and adipocytes, and we recently showed that the levels of 
GDF-15 in mice are 2- to 60-fold higher in the liver, lungs 
and kidney than in the cardiac muscle [19]. Therefore, this 
marker reflects changes in many organs, not just in the car-
diac ventricles and atria, and might therefore be less likely 
to be load-dependent as compared with NT-proBNP. Since 
levels of GDF-15 are independent of the presence of AF in 
patients with HF, it may better reflect HF patients’ overall 
clinical condition, including non-cardiac comorbidities [20].
Previous studies have shown that the levels of GDF-15 
in AF patients without HF are fairly similar to the levels 
in community-dwelling elderly [21]. In the AF field, GDF-
15 is of increasing interest since this biomarker was the 
strongest predictor of major bleeding, stroke and mortality 
in the ARISTOTLE trial (the Apixaban for Reduction in 
Stroke and Other Thromboembolic Events in Atrial Fibril-
lation) and RE-LY (Randomized Evaluation of Long-Term 
Anticoagulant Therapy), and is one of the strongest prog-
nostic factors in the ABC (age, biomarkers, comorbidities) 
score, the new score for assessing risk of AF patients [22, 
23].
The diagnosis of HF (especially HFpEF) in patients with 
AF remains a clinical challenge, since signs and symptoms, 
echocardiographic abnormalities and elevated NT-proBNP 
levels can be caused by both AF alone and by AF with 
concomitant HFpEF. Since GDF-15 has previously been 
shown to have diagnostic utility in HFpEF, with similarly 
or even more elevated levels as compared with patients with 
HFrEF, and seems to be less influenced by concomitant AF 
in patients with HF as shown in the present study, it could 
perhaps be a suitable companion marker next to NT-proBNP 
to diagnose the presence or absence of HFpEF in patients 
presenting with AF [9, 24, 25]. This novel hypothesis should 
be further explored by studying the potential usefulness of 
GDF-15 and its clinical consequences. The combination 
of GDF-15 and NT-proBNP to distinguish AF versus HF 
by additionally comparing levels in patients with AF with-
out HF, as well as by comparing levels in patients with AF 
before and after cardioversion needs further investigation.
In clinical practice, NP levels are often used for therapy 
guidance, but these levels can fluctuate in patients with HF 
and paroxysmal AF, depending on whether they are in SR or 
AF at the time of measurement [26, 27]. Since NT-proBNP 
is mainly produced and secreted by the cardiomyocytes in 
the atria and ventricles in response to haemodynamic wall 
stress, this marker is known to be sensitive to heart rate and 
rhythm disturbances [5, 7].
As described previously, most contemporary clinical HF 
trials use different NP thresholds for the inclusion of patients 
with and without AF [28–30]. These higher thresholds in 
patients with AF increase the probability that these patients 
have actual underlying HF, instead of including patients who 
have merely AF—a distinction that is especially challeng-
ing in patients with HFpEF and AF [31]. For patients with a 
history of AF but who are in SR at time of blood collection, 
Table 2  Multivariable differences of the plasma levels of NT-proBNP and GDF-15 between the three rhythm groups in the index and validation 
cohort
Index cohort
NT-proBNP GDF-15
AF at baseline AF at baseline
History of AF—SR at baseline History of AF—SR at baseline
Sinus rhythm Sinus rhythm
Validation cohort
NT-proBNP GDF-15
AF at baseline AF at baseline
History of AF—SR at baseline History of AF—SR at baseline
Sinus rhythm Sinus rhythm
p < 0.001
p<0.001
p<0.001
p=0.02 NS
NS
NS
NS
Adjusted for age, sex, body mass index, left ventricular ejection fraction, heart rate, estimated glomerular filtration rate, a previous myocardial 
infarction, diabetes mellitus, and the use of ACE-inhibitors/ARBs and beta-blockers at baseline
NT-proBNP N-terminal pro-B-type natriuretic peptide, GDF15 growth differentiation factor 15, NYHA New York Heart Association, BMI body 
mass index, LVEF left ventricular ejection fraction, eGFR estimated glomerular filtration rate, NS non-significant
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it is often unclear which threshold to use. This study shows 
for the first time that patients with a history of AF but who 
have SR at the time of measurement, have NT-proBNP levels 
that are much lower and more similar to those patients who 
have never had AF before, as compared to patients who have 
AF at time of measurement. Using a higher NP threshold for 
patients in SR but with a history of AF could result in inap-
propriately high screen failure rates in clinical trials. In these 
clinical HF trials, GDF-15 might be considered as an addi-
tional marker to distinguish severity of HF apart from AF.
Limitations
Limitations of this study include the post hoc design. There 
was a lack of information about the duration between the 
last episode of AF and screening and number/type of AF 
episodes the patient had experienced before. Asymptomatic 
patients with paroxysmal AF could have been missed and 
regarded as SR patients. Furthermore, no echocardiography 
data apart from LVEF was available. The NT-proBNP cutoff 
for inclusion in the BIOSTAT-CHF index cohort could have 
potentially led to higher inclusion rates of SR patients with 
more severe HF as compared with those with AF, and as 
compared with patients included in the validation cohort. 
However, even though this inclusion criterion differed, simi-
lar biomarker patterns were observed in both the index and 
validation cohort, which is a strength of the present study. 
Unfortunately, we were not able to further stratify the index 
and validation cohort in HFrEF and HFpEF, since this would 
have importantly limited the number of patients in the three 
rhythm groups within these three HF subtypes.
Conclusion
The plasma levels of NT-proBNP in HF patients were sig-
nificantly influenced by the presence of AF at time of meas-
urement, whereas the plasma levels of GDF-15 were inde-
pendent of underlying AF. Therefore, GDF-15 might have 
additive value combined with NT-proBNP in the assessment 
of patients with HF and concomitant AF.
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